Capital Health Collaborates with TVAX Biomedical on Brain Cancer Immunotherapy Trial

Tuesday, July 09, 2024

Capital Health Cancer Center has recently partnered with TVAX Biomedical, Inc. to conduct a clinical trial exploring a potential new therapy for glioblastoma (GBM), the most common form of malignant brain cancer.

This collaboration positions Capital Health as one of five clinical sites in the United States offering access to the TVAX trial, and currently the only East Coast location north of Florida.

The pivotal role of clinical trials in delivering exceptional patient care.Highlighted the trial's potential to introduce a groundbreaking therapy for GBM, utilizing patients' own tumor cells to create a vaccine that stimulates a targeted immune response against their cancer.

Previous attempts over the last two decades to leverage the immune system against GBM have not yielded effective results. The TVAX protocol represents a novel approach by using patients' tumor cells to develop a vaccine.

This vaccine aims to activate and expand anti-tumor immune cells, potentially overcoming the immune suppression characteristic of GBM.

The study aims to assess whether this strategy can effectively empower the immune system to eliminate residual tumor cells.

The personalized nature of this treatment approach. By harnessing the patient's own immune system to target cancer cells, the study holds promise for improving outcomes in GBM treatment.

Optimism about the trial's potential impact on patients and families facing brain tumors like glioblastoma.

CEO of TVAX Biomedical, expressed appreciation for Capital Health's participation and the expertise of its clinical team. He emphasized the trial's significance in advancing treatment options for GBM patients, who currently have limited therapeutic choices.

The TVAX clinical trial at Capital Health Cancer Center is open to adults aged 18 to 80 with newly diagnosed glioblastoma and an active methylguanine methyltransferase (MGMT) status.

Candidates must undergo screening to determine their eligibility for participation, including the ability to undergo surgery at Capital Health for cell collection necessary for vaccine production.


Harvard Medical School - Leadership in Medicine Southeast Asia47th IHF World Hospital Congress